OPKO Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on November 5, 2015. The report details a material definitive agreement entered into by Bio-Reference Laboratories, Inc. (BRLI), a wholly-owned subsidiary of the Company, with JPMorgan Chase Bank, N.A.
Key Financial Metrics and Debt Structure
- New Credit Facility: A secured revolving credit facility of $175.0 million.
- Expansion Option: The facility may be increased to up to $275.0 million subject to specified conditions.
- Sub-facilities: Includes a $20.0 million swingline loan sub-facility and a $20.0 million letters of credit sub-facility.
- Maturity Date: November 5, 2020.
- Interest Rates:
- CB Floating Rate: Prime or LIBOR (1-month) + 2.50%, plus an applicable margin of 0.35% for the first 12 months and 0.50% thereafter.
- LIBOR Rate: LIBOR (adjusted) plus an applicable margin of 1.35% for the first 12 months and 1.50% thereafter.
- Fees: Unused commitment fee of 0.25% of lending commitments.
- Collateral: Secured by substantially all assets of BRLI and its domestic subsidiaries, plus a non-recourse pledge by OPKO Health of its equity interest in BRLI.
Material Changes Versus Prior Period
The New Credit Agreement replaces the Existing Loan Agreement with PNC Bank, National Association, which has been terminated. The proceeds from the new facility are designated to refinance existing indebtedness, finance working capital needs, and serve general corporate purposes for BRLI and its subsidiaries.
Management Commentary, Risks, and Covenants
The agreement includes customary covenants and restrictions. Key provisions include:
- Covenants: BRLI must maintain a minimum fixed charge coverage ratio if availability falls below a specified amount and must comply with applicable laws.
- Restrictions: Limitations on incurring additional indebtedness, paying dividends, and making certain distributions to the Company, subject to exceptions.
- Default Risks: Failure to comply with covenants constitutes an event of default, even if debt service obligations are met. Remedies include acceleration of repayment and execution upon collateral.
Availability under the agreement is based on a borrowing base comprised of eligible accounts receivables of BRLI and certain subsidiaries.
Investor Verification Checklist
- Verify the exact amount of indebtedness refinanced from the terminated PNC Bank agreement.
- Confirm the current utilization rate of the $175.0 million facility and the status of the borrowing base (eligible accounts receivable).
- Review the specific threshold for the minimum fixed charge coverage ratio covenant.
- Assess the impact of the non-recourse pledge of OPKO Health's equity interest in BRLI on the parent company's balance sheet.
- Check for any subsequent amendments to the interest rate margins or facility expansion conditions.
Note: This filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period.